JP2012525329A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012525329A5 JP2012525329A5 JP2012506649A JP2012506649A JP2012525329A5 JP 2012525329 A5 JP2012525329 A5 JP 2012525329A5 JP 2012506649 A JP2012506649 A JP 2012506649A JP 2012506649 A JP2012506649 A JP 2012506649A JP 2012525329 A5 JP2012525329 A5 JP 2012525329A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- cancer
- diazenyl
- dimethylamino
- cooch
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims 26
- 201000011510 cancer Diseases 0.000 claims 26
- -1 CF 3 Inorganic materials 0.000 claims 21
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 125000003342 alkenyl group Chemical group 0.000 claims 18
- 125000000217 alkyl group Chemical group 0.000 claims 18
- 125000000524 functional group Chemical group 0.000 claims 17
- 150000001875 compounds Chemical class 0.000 claims 16
- 150000003839 salts Chemical class 0.000 claims 13
- 208000019553 vascular disease Diseases 0.000 claims 13
- 229910052799 carbon Inorganic materials 0.000 claims 12
- 125000002723 alicyclic group Chemical group 0.000 claims 9
- 125000003545 alkoxy group Chemical group 0.000 claims 9
- 150000003973 alkyl amines Chemical class 0.000 claims 9
- 125000003118 aryl group Chemical group 0.000 claims 9
- 229910052794 bromium Inorganic materials 0.000 claims 9
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 9
- 229910052801 chlorine Inorganic materials 0.000 claims 9
- 229910052731 fluorine Inorganic materials 0.000 claims 9
- 125000000623 heterocyclic group Chemical group 0.000 claims 9
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 9
- 239000003085 diluting agent Substances 0.000 claims 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims 7
- 239000003937 drug carrier Substances 0.000 claims 6
- 239000002246 antineoplastic agent Substances 0.000 claims 5
- 230000008512 biological response Effects 0.000 claims 5
- 229940127089 cytotoxic agent Drugs 0.000 claims 5
- 239000003607 modifier Substances 0.000 claims 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 101100516572 Caenorhabditis elegans nhr-8 gene Proteins 0.000 claims 3
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 3
- 125000002619 bicyclic group Chemical group 0.000 claims 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 3
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 229910052711 selenium Inorganic materials 0.000 claims 3
- 150000005082 selenophenes Chemical class 0.000 claims 3
- JPQZIMZXMPFINA-UHFFFAOYSA-N 2H-selenopheno[2,3-b]pyridin-4-one Chemical compound [Se]1CC=C2C1=NC=CC2=O JPQZIMZXMPFINA-UHFFFAOYSA-N 0.000 claims 2
- PGFSGRJPVDGAES-UHFFFAOYSA-N 3-(dimethylaminodiazenyl)-4,5,6,7-tetrahydro-1-benzoselenophene-2-carboxamide Chemical compound C1CCCC2=C1C(N=NN(C)C)=C(C(N)=O)[se]2 PGFSGRJPVDGAES-UHFFFAOYSA-N 0.000 claims 2
- ITKGRVHKZRMGOW-UHFFFAOYSA-N 3-(dimethylaminodiazenyl)-4,5,6,7-tetrahydro-1-benzoselenophene-2-carboxylic acid Chemical compound C1CCCC2=C1C(N=NN(C)C)=C(C(O)=O)[se]2 ITKGRVHKZRMGOW-UHFFFAOYSA-N 0.000 claims 2
- QRCDRZSHXOQWBT-UHFFFAOYSA-N 3-(dimethylaminodiazenyl)-5-phenylselenophene-2-carboxamide Chemical compound [se]1C(C(N)=O)=C(N=NN(C)C)C=C1C1=CC=CC=C1 QRCDRZSHXOQWBT-UHFFFAOYSA-N 0.000 claims 2
- MTHJYPBKWFMWLW-UHFFFAOYSA-N 3-(dimethylaminodiazenyl)-5-phenylselenophene-2-carboxylic acid Chemical compound [se]1C(C(O)=O)=C(N=NN(C)C)C=C1C1=CC=CC=C1 MTHJYPBKWFMWLW-UHFFFAOYSA-N 0.000 claims 2
- LQWXNVPLUYRRDP-UHFFFAOYSA-N 3-(dimethylaminodiazenyl)selenopheno[2,3-b]pyridine-2-carboxamide Chemical compound C1=CC=C2C(N=NN(C)C)=C(C(N)=O)[se]C2=N1 LQWXNVPLUYRRDP-UHFFFAOYSA-N 0.000 claims 2
- TUKMABIAASUVMR-UHFFFAOYSA-N 3-(dimethylaminodiazenyl)selenopheno[2,3-b]pyridine-2-carboxylic acid Chemical compound C1=CC=C2C(N=NN(C)C)=C(C(O)=O)[se]C2=N1 TUKMABIAASUVMR-UHFFFAOYSA-N 0.000 claims 2
- JTOLZOPDDNSDTG-UHFFFAOYSA-N 3-methyl-6,7,8,9-tetrahydro-[1]benzoselenolo[3,2-d]triazin-4-one Chemical compound C1CCCC2=C1C(N=NN(C1=O)C)=C1[se]2 JTOLZOPDDNSDTG-UHFFFAOYSA-N 0.000 claims 2
- JSQKUQADJPSHMN-UHFFFAOYSA-N 3-methyl-6-phenylselenopheno[3,2-d]triazin-4-one Chemical compound [se]1C=2C(=O)N(C)N=NC=2C=C1C1=CC=CC=C1 JSQKUQADJPSHMN-UHFFFAOYSA-N 0.000 claims 2
- CRUSSEBHSSZTHD-UHFFFAOYSA-N 4-(dimethylaminodiazenyl)-5-methylselenophene-2-carboxamide Chemical compound CN(C)N=NC=1C=C(C(N)=O)[se]C=1C CRUSSEBHSSZTHD-UHFFFAOYSA-N 0.000 claims 2
- AXDXBJXTPGZQSP-UHFFFAOYSA-N 5-tert-butyl-3-(dimethylaminodiazenyl)selenophene-2-carboxamide Chemical compound CN(C)N=NC=1C=C(C(C)(C)C)[se]C=1C(N)=O AXDXBJXTPGZQSP-UHFFFAOYSA-N 0.000 claims 2
- LNRMPAFIJJUNBQ-UHFFFAOYSA-N 5-tert-butyl-3-(dimethylaminodiazenyl)selenophene-2-carboxylic acid Chemical compound CN(C)N=NC=1C=C(C(C)(C)C)[se]C=1C(O)=O LNRMPAFIJJUNBQ-UHFFFAOYSA-N 0.000 claims 2
- JAKWOPDPFUFEOT-UHFFFAOYSA-N 6-tert-butyl-3-methylselenopheno[3,2-d]triazin-4-one Chemical compound O=C1N(C)N=NC2=C1[se]C(C(C)(C)C)=C2 JAKWOPDPFUFEOT-UHFFFAOYSA-N 0.000 claims 2
- 108010092160 Dactinomycin Proteins 0.000 claims 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims 2
- IAQNAZWFFCPLQQ-UHFFFAOYSA-N [Se]1C(=CC=C1C(=O)N)C(=O)N Chemical compound [Se]1C(=CC=C1C(=O)N)C(=O)N IAQNAZWFFCPLQQ-UHFFFAOYSA-N 0.000 claims 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 229960004679 doxorubicin Drugs 0.000 claims 2
- 229960002949 fluorouracil Drugs 0.000 claims 2
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 claims 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims 2
- MDUAKGGGVUCBPX-UHFFFAOYSA-N selenophen-3-one Chemical compound [Se]1C=CC(C1)=O MDUAKGGGVUCBPX-UHFFFAOYSA-N 0.000 claims 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 1
- HVWOVKZNKRKHPL-UHFFFAOYSA-N 5-tert-butyl-3-(dimethylaminodiazenyl)selenophene-2-carbonitrile Chemical compound CN(C)N=NC=1C=C(C(C)(C)C)[se]C=1C#N HVWOVKZNKRKHPL-UHFFFAOYSA-N 0.000 claims 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims 1
- 108010006654 Bleomycin Proteins 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 101100294115 Caenorhabditis elegans nhr-4 gene Proteins 0.000 claims 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 claims 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 102000015696 Interleukins Human genes 0.000 claims 1
- 108010063738 Interleukins Proteins 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims 1
- 229930192392 Mitomycin Natural products 0.000 claims 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 206010031112 Oropharyngeal squamous cell carcinoma Diseases 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 1
- 229930183665 actinomycin Natural products 0.000 claims 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims 1
- 210000004100 adrenal gland Anatomy 0.000 claims 1
- 229960003437 aminoglutethimide Drugs 0.000 claims 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 claims 1
- 229960002932 anastrozole Drugs 0.000 claims 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 229960001561 bleomycin Drugs 0.000 claims 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- KVUAALJSMIVURS-ZEDZUCNESA-L calcium folinate Chemical compound [Ca+2].C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-ZEDZUCNESA-L 0.000 claims 1
- 235000008207 calcium folinate Nutrition 0.000 claims 1
- 239000011687 calcium folinate Substances 0.000 claims 1
- 229960004117 capecitabine Drugs 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- 229960002286 clodronic acid Drugs 0.000 claims 1
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 229940047120 colony stimulating factors Drugs 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 229960000640 dactinomycin Drugs 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 229960001904 epirubicin Drugs 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 229960005420 etoposide Drugs 0.000 claims 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
- 229960000255 exemestane Drugs 0.000 claims 1
- YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 claims 1
- 229960001751 fluoxymesterone Drugs 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 229940047124 interferons Drugs 0.000 claims 1
- 229940047122 interleukins Drugs 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 229960003881 letrozole Drugs 0.000 claims 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims 1
- 229960002293 leucovorin calcium Drugs 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 229960001786 megestrol Drugs 0.000 claims 1
- 229960004296 megestrol acetate Drugs 0.000 claims 1
- 229960001428 mercaptopurine Drugs 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 208000021039 metastatic melanoma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 229960004857 mitomycin Drugs 0.000 claims 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims 1
- 229960001156 mitoxantrone Drugs 0.000 claims 1
- 208000022698 oropharynx squamous cell carcinoma Diseases 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 claims 1
- 229940046231 pamidronate Drugs 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000001817 pituitary effect Effects 0.000 claims 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 1
- 229960004618 prednisone Drugs 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 210000000952 spleen Anatomy 0.000 claims 1
- 229960001603 tamoxifen Drugs 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 229960001196 thiotepa Drugs 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
- 229960003048 vinblastine Drugs 0.000 claims 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 1
- 229960004528 vincristine Drugs 0.000 claims 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims 1
- 229960002066 vinorelbine Drugs 0.000 claims 1
- 0 C*(*=NC1=C2C(C)(*)**(C)*C1(C)C)C2=O Chemical compound C*(*=NC1=C2C(C)(*)**(C)*C1(C)C)C2=O 0.000 description 5
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN959/CHE/2009 | 2009-04-27 | ||
| IN959CH2009 | 2009-04-27 | ||
| PCT/IN2010/000262 WO2010125575A1 (en) | 2009-04-27 | 2010-04-26 | Anti-cancer drugs, and uses relating for malignant melanoma and other cancers |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012525329A JP2012525329A (ja) | 2012-10-22 |
| JP2012525329A5 true JP2012525329A5 (enExample) | 2013-05-30 |
| JP5571168B2 JP5571168B2 (ja) | 2014-08-13 |
Family
ID=42992332
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012506649A Expired - Fee Related JP5571168B2 (ja) | 2009-04-27 | 2010-04-26 | 抗癌剤ならびに悪性黒色腫および他の癌に関連する使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8143237B2 (enExample) |
| EP (1) | EP2424351B1 (enExample) |
| JP (1) | JP5571168B2 (enExample) |
| KR (1) | KR20120006554A (enExample) |
| CN (1) | CN102438449B (enExample) |
| AU (1) | AU2010243213B2 (enExample) |
| BR (1) | BRPI1006651A2 (enExample) |
| CA (1) | CA2759519A1 (enExample) |
| IL (1) | IL215789A0 (enExample) |
| NZ (1) | NZ595602A (enExample) |
| WO (1) | WO2010125575A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2640392B1 (en) * | 2010-11-18 | 2015-01-07 | Kasina Laila Innova Pharmaceuticals Private Ltd. | Substituted 4-(selenophen-2(or 3)-ylamino)pyrimidine compounds and methods of use thereof |
| US9090633B2 (en) | 2010-11-18 | 2015-07-28 | Kasina Laila Innova Pharmaceuticals Private Limited | Substituted 4-(arylamino) selenophenopyrimidine compounds and methods of use thereof |
| AU2011340063B2 (en) * | 2010-12-09 | 2016-03-24 | Kasina Laila Innova Pharmaceuticals Private Limited | Substituted 4-(arylamino) selenophenopyrimidine compounds and methods of use thereof |
| WO2012176212A1 (en) | 2011-06-20 | 2012-12-27 | V.B. Medicare Pvt. Ltd. | Carrier based nanogel formulation for skin targeting. |
| EP2762472B1 (en) * | 2011-09-28 | 2017-05-24 | Industry-Academia Cooperation Group of Sejong University | Selenophene-fused aromatic compound and manufacturing method thereof |
| KR101418776B1 (ko) | 2011-09-28 | 2014-07-14 | 사회복지법인 삼성생명공익재단 | 셀레노펜-접합 방향족 화합물, 및 이의 제조 방법 |
| WO2014012000A2 (en) | 2012-07-12 | 2014-01-16 | Euclises Pharmaceuticals, Inc. | No-releasing guanidine-coxib anti-cancer agents |
| WO2014012074A2 (en) | 2012-07-12 | 2014-01-16 | Euclises Pharmaceuticals, Inc. | No-releasing nonoate (nitrogen-bound) sulfonamide-linked-coxib anti-cancer agents |
| WO2014018888A1 (en) | 2012-07-26 | 2014-01-30 | Confluence Life Sciences Inc. | 4-alkoxy/aralkoxy-5-substituted-pyrrolopyrimidine compounds as tak1 inhibitors in disease treatment |
| US20150353542A1 (en) | 2013-01-14 | 2015-12-10 | Amgen Inc. | Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture |
| AU2016209046A1 (en) | 2015-01-23 | 2017-07-20 | Aclaris Therapeutics, Inc. | Heterocyclic ITK inhibitors for treating inflammation and cancer |
| CN108129475A (zh) * | 2018-02-08 | 2018-06-08 | 中南大学湘雅三医院 | 一种生物光敏剂及其制备方法和应用 |
| KR102648781B1 (ko) | 2021-11-09 | 2024-03-19 | 국립공주대학교 산학협력단 | 항암 활성을 갖는 인데노피라졸론 유도체 화합물, 그의 제조방법 및 그의 용도 |
| CN121712769A (zh) * | 2023-06-29 | 2026-03-20 | 艾健科学股份有限公司 | 新型硒吩衍生物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6620804B2 (en) * | 1996-06-03 | 2003-09-16 | Purdue Research Foundation | Selenophene anti-tumor agents |
| ATE247955T1 (de) * | 1996-06-03 | 2003-09-15 | Purdue Research Foundation | Selenophen-antitumormittel |
| US20100183726A1 (en) | 2006-08-02 | 2010-07-22 | Robert Nicolosi | Compositions and methods for treating cancer with dacarbazine nanoemulsions |
| BRPI0913485A2 (pt) * | 2008-09-15 | 2016-06-07 | Kasina Laila Innova Pharmaceuticals Private Ltd | medicamentos anticâncer e usos relacionados para melanoma maligno metastático e outros cânceres. |
-
2010
- 2010-04-26 BR BRPI1006651-9A patent/BRPI1006651A2/pt not_active IP Right Cessation
- 2010-04-26 WO PCT/IN2010/000262 patent/WO2010125575A1/en not_active Ceased
- 2010-04-26 JP JP2012506649A patent/JP5571168B2/ja not_active Expired - Fee Related
- 2010-04-26 KR KR1020117027765A patent/KR20120006554A/ko not_active Ceased
- 2010-04-26 CN CN201080016304.7A patent/CN102438449B/zh not_active Expired - Fee Related
- 2010-04-26 US US12/767,647 patent/US8143237B2/en not_active Expired - Fee Related
- 2010-04-26 AU AU2010243213A patent/AU2010243213B2/en not_active Ceased
- 2010-04-26 NZ NZ595602A patent/NZ595602A/xx unknown
- 2010-04-26 CA CA2759519A patent/CA2759519A1/en not_active Abandoned
- 2010-04-26 EP EP10769410.1A patent/EP2424351B1/en not_active Not-in-force
-
2011
- 2011-10-23 IL IL215789A patent/IL215789A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5502072B2 (ja) | オーロラキナーゼ阻害剤としての縮合二環式ピリミジン化合物 | |
| US9765058B2 (en) | Substituted benzylpyrazoles | |
| CN102232071B (zh) | 作为蛋白激酶抑制剂的稠合多环化合物 | |
| JP6664385B2 (ja) | Ｂｕｂ１阻害薬としてのベンジル置換インダゾール類 | |
| JP6873145B2 (ja) | ５−置換２−（モルホリン−４−イル）−１，７−ナフチリジン | |
| KR101817221B1 (ko) | 치환된 4-(셀레노펜-2(또는 3)-일아미노)피리미딘 화합물 및 이의 사용방법 | |
| JP5781934B2 (ja) | チロシンキナーゼ阻害剤としての融合２環および３環ピリミジン化合物 | |
| JP6173430B2 (ja) | アミノ置換イミダゾピリダジン | |
| JP2014503567A5 (enExample) | ||
| WO2020010197A1 (en) | Fused pyrazine derivatives as a2a / a2b inhibitors | |
| JP2008156336A5 (enExample) | ||
| KR20170106452A (ko) | 4Ｈ-피롤로［3,2-ｃ］피리딘-4-온 유도체 | |
| JP2012502900A5 (enExample) | ||
| AU2014249003A1 (en) | Novel compounds and compositions for inhibition of FASN | |
| JP2015537017A (ja) | アミノイミダゾピリダジン類 | |
| JP2020536971A5 (enExample) | ||
| JP2022526831A (ja) | ヘテロ環式化合物およびその使用 | |
| JP2015504076A5 (enExample) | ||
| JP2017530963A (ja) | ベンジル置換インダゾール類 | |
| US10851054B2 (en) | Derivatives of indole for the treatment of cancer, viral infections and lung diseases | |
| WO2013174743A1 (en) | Substituted pyrrolopyrimidines | |
| JP2019504826A (ja) | ヘテロ−１，５，６，７−テトラヒドロ−４ｈ−インドール−４−オン類 | |
| KR20130126653A (ko) | 치환된 4-(아릴아미노) 셀레노페노피리미딘 화합물 및 이의 사용방법 | |
| NZ787908A (en) | Modulators of the integrated stress pathway | |
| HK1151694B (en) | Fused bicyclic pyrimidine compounds as aurora kinase inhibitors |